title: Clinical experience with daptomycin for the treatment of patients with knee and hip periprosthetic joint infections.
abstract: OBJECTIVE
  To investigate the clinical efficacy and safety of daptomycin in the treatment of hip and knee periprosthetic joint infections (PJIs).
  
  
  METHODS
  We completed a retrospective review of all patients in our institution (n=20) who were treated with daptomycin for hip or knee PJI, over the 36 month period from January 2008 until December 2010.
  
  
  RESULTS
  Infection types included eight cases with acute infections, nine cases of chronic infection and three cases of positive intraoperative cultures. Methicillin-resistant coagulase-negative Staphylococcus was the most frequent microorganism found in surgical cultures (40%). Our patients, on average, received daptomycin as salvage therapy at a dose of 6.6 mg/kg/day for 44.9 days. The overall success rate was 78.6% after a median follow-up period of 20 months. In the subgroup of patients with acute PJIs, treatment with daptomycin, debridement and implant retention was successful in all cases. We found two cases of severe side effects (one case of acute renal failure due to massive rhabdomyolysis and one of eosinophilic pneumonia) and two cases of asymptomatic transient creatine phosphokinase (CPK) level elevation.
  
  
  CONCLUSIONS
  The combination of high daptomycin doses with an adequate surgical approach could be a viable alternative in cases of difficult-to-treat Gram-positive PJIs. Due to the risk of potentially serious adverse events, serum CPK level should be closely monitored.
authors.affiliation: Department of Orthopaedic Surgery, Reconstructive and Septic Surgery Division, Hospital Universitario Vall d'Hebron, Universitat Autónoma de Barcelona, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain. pcorona@vhebron.net
authors.forename: Pablo S
authors.initials: PS
authors.lastname: Corona Pérez-Cardona
authors.forename: Victor
authors.initials: V
authors.lastname: Barro Ojeda
authors.forename: Dolors
authors.initials: D
authors.lastname: Rodriguez Pardo
authors.forename: Carlos
authors.initials: C
authors.lastname: Pigrau Serrallach
authors.forename: Ernesto
authors.initials: E
authors.lastname: Guerra Farfán
authors.forename: Carles
authors.initials: C
authors.lastname: Amat Mateu
authors.forename: Xavier
authors.initials: X
authors.lastname: Flores Sanchez
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001419:Bacteria / Q000145:classification / Q000302:isolation & purification; D001424:Bacterial Infections / Q000188:drug therapy / Q000601:surgery; D017576:Daptomycin / Q000009:adverse effects / Q000627:therapeutic use*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology; D005260:Female; D006622:Hip Prosthesis; D006801:Humans; D007720:Knee Prosthesis; D008297:Male; D008875:Middle Aged; D015207:Osteoarthritis, Hip / Q000188:drug therapy* / Q000601:surgery; D020370:Osteoarthritis, Knee / Q000188:drug therapy* / Q000601:surgery; D016459:Prosthesis-Related Infections / Q000188:drug therapy* / Q000601:surgery; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D017576:Daptomycin